Brett A Schroeder
Overview
Explore the profile of Brett A Schroeder including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
150
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Karlina I, Schroeder B, Kirgizov K, Romantsova O, Istranov A, Nedorubov A, et al.
J Bone Oncol
. 2022 Jul;
35:100440.
PMID: 35855933
Ewing's sarcoma (ES) is an aggressive malignant tumor commonly affecting adolescents. The standard of care includes surgical treatment and systemic therapies, although ES patients often develop drug resistance, leading to...
12.
Schroeder B, Jess J, Sankaran H, Shah N
Curr Opin Hematol
. 2022 Jul;
29(4):225-232.
PMID: 35787551
Purpose Of Review: The purpose of this review is to summarize the status and utilization of chimeric antigen receptor T-cell (CAR-T) therapy based on the most recent clinical trials in...
13.
Fayzullina D, Tsibulnikov S, Stempen M, Schroeder B, Kumar N, Kharwar R, et al.
Cancers (Basel)
. 2022 Apr;
14(8).
PMID: 35454895
Ewing sarcoma (ES) is an uncommon cancer that arises in mesenchymal tissues and represents the second most widespread malignant bone neoplasm after osteosarcoma in children. Amplifications in genomic, proteomic, and...
14.
Zhang S, Black R, Kohli K, Hayes B, Miller C, Koehne A, et al.
Mol Cancer Ther
. 2022 Apr;
21(6):999-1009.
PMID: 35405743
One obstacle for human solid tumor immunotherapy research is the lack of clinically relevant animal models. In this study, we sought to establish a chimeric antigen receptor (CAR) T-cell treatment...
15.
Schroeder B, Zhang Y, Smythe K, Desai P, Thomas A, Viveiros P, et al.
Cancers (Basel)
. 2022 Mar;
14(5).
PMID: 35267598
Patients with metastatic soft tissue sarcoma (STS) have a poor prognosis and few available systemic treatment options. Trabectedin is currently being investigated as a potential adjunct to immunotherapy as it...
16.
Schroeder B, LaFranzo N, LaFleur B, Gittelman R, Vignali M, Zhang S, et al.
J Immunother Cancer
. 2021 Sep;
9(8).
PMID: 34465597
Background: Dedifferentiated liposarcoma (DDLPS) is one of the most common soft tissue sarcoma subtypes and is devastating in the advanced/metastatic stage. Despite the observation of clinical responses to inhibitors, little...
17.
Kohli K, Yao L, Nowicki T, Zhang S, Black R, Schroeder B, et al.
J Immunother Cancer
. 2021 May;
9(5).
PMID: 33963013
Background: Synovial sarcoma (SS) and myxoid/round cell liposarcoma (MRCL) are ideal solid tumors for the development of adoptive cellular therapy (ACT) targeting NY-ESO-1, as a high frequency of tumors homogeneously...
18.
Pollack S, Redman M, Baker K, Wagner M, Schroeder B, Loggers E, et al.
JAMA Oncol
. 2020 Sep;
6(11):1778-1782.
PMID: 32910151
Importance: Anthracycline-based therapy is standard first-line treatment for most patients with advanced and metastatic sarcomas. Although multiple trials have attempted to show improved outcomes in patients with soft-tissue sarcoma over...
19.
Schroeder B, Black R, Spadinger S, Zhang S, Kohli K, Cao J, et al.
J Immunother Cancer
. 2020 Apr;
8(1).
PMID: 32269142
Background: Adoptive cellular therapy (ACT) is a promising treatment for synovial sarcoma (SS) with reported response rates of over 50%. However, more work is needed to obtain deeper and more...
20.
Schroeder B, Kohli K, OMalley R, Kim T, Jones R, Pierce R, et al.
Oncoimmunology
. 2020 Feb;
9(1):1710064.
PMID: 32002307
Gastrointestinal stromal tumor (GIST) is a devastating disease, especially in the setting of metastasis. The natural progression of GIST has been significantly altered by the development of small molecule tyrosine...